EGF receptor as a therapeutic target: Patient selection and mechanisms of resistance to receptor-targeted drugs

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Emerging results from clinical trials of epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and at best modest to no clinical activity in a variety of human carcinomas. The lack of molecular evidence to suggest a pathogenic role for the EGFR in most common solid tumors is not inconsistent with the modest clinical activity observed in these single-agent trials. In addition, the lack of enrollment of patients with EGFR-dependent tumors onto these trials leaves open the possibility that these studies may have included some tumors that benefited from these therapies but for which this benefit was diluted and thus not detected within the enrolled patient population at large. These considerations suggest that the enrollment of unselected patients onto trials with EGFR inhibitors should be revisited to identify a cohort of EGFRdependent tumors against which EGFR inhibitors might exhibit clinical activity. This approach would also exclude patients for whom these drugs will not induce any clinical benefit.

Original languageEnglish (US)
Pages (from-to)289s-291s
JournalJournal of Clinical Oncology
Volume21
Issue number23
DOIs
StatePublished - Dec 1 2003

Fingerprint

Drug Receptors
Epidermal Growth Factor Receptor
Patient Selection
Neoplasms
Therapeutics
Clinical Trials
Carcinoma
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{aff2807c12044d849a5ddd2a7694e30d,
title = "EGF receptor as a therapeutic target: Patient selection and mechanisms of resistance to receptor-targeted drugs",
abstract = "Emerging results from clinical trials of epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and at best modest to no clinical activity in a variety of human carcinomas. The lack of molecular evidence to suggest a pathogenic role for the EGFR in most common solid tumors is not inconsistent with the modest clinical activity observed in these single-agent trials. In addition, the lack of enrollment of patients with EGFR-dependent tumors onto these trials leaves open the possibility that these studies may have included some tumors that benefited from these therapies but for which this benefit was diluted and thus not detected within the enrolled patient population at large. These considerations suggest that the enrollment of unselected patients onto trials with EGFR inhibitors should be revisited to identify a cohort of EGFRdependent tumors against which EGFR inhibitors might exhibit clinical activity. This approach would also exclude patients for whom these drugs will not induce any clinical benefit.",
author = "Arteaga, {Carlos L.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1200/JCO.2003.10.523",
language = "English (US)",
volume = "21",
pages = "289s--291s",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - EGF receptor as a therapeutic target

T2 - Patient selection and mechanisms of resistance to receptor-targeted drugs

AU - Arteaga, Carlos L.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Emerging results from clinical trials of epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and at best modest to no clinical activity in a variety of human carcinomas. The lack of molecular evidence to suggest a pathogenic role for the EGFR in most common solid tumors is not inconsistent with the modest clinical activity observed in these single-agent trials. In addition, the lack of enrollment of patients with EGFR-dependent tumors onto these trials leaves open the possibility that these studies may have included some tumors that benefited from these therapies but for which this benefit was diluted and thus not detected within the enrolled patient population at large. These considerations suggest that the enrollment of unselected patients onto trials with EGFR inhibitors should be revisited to identify a cohort of EGFRdependent tumors against which EGFR inhibitors might exhibit clinical activity. This approach would also exclude patients for whom these drugs will not induce any clinical benefit.

AB - Emerging results from clinical trials of epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and at best modest to no clinical activity in a variety of human carcinomas. The lack of molecular evidence to suggest a pathogenic role for the EGFR in most common solid tumors is not inconsistent with the modest clinical activity observed in these single-agent trials. In addition, the lack of enrollment of patients with EGFR-dependent tumors onto these trials leaves open the possibility that these studies may have included some tumors that benefited from these therapies but for which this benefit was diluted and thus not detected within the enrolled patient population at large. These considerations suggest that the enrollment of unselected patients onto trials with EGFR inhibitors should be revisited to identify a cohort of EGFRdependent tumors against which EGFR inhibitors might exhibit clinical activity. This approach would also exclude patients for whom these drugs will not induce any clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=0642337954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642337954&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.10.523

DO - 10.1200/JCO.2003.10.523

M3 - Article

C2 - 14645415

AN - SCOPUS:0642337954

VL - 21

SP - 289s-291s

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -